|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 355.70 USD | -1.12% |
|
-2.67% | -6.37% |
| 11/06 | Piper Sandler Initiates Waters at Neutral With $400 Price Target | MT |
| 08/06 | Waters Corporation Launches BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 17.41 | 17.32 | 13.54 | 11.4 | 11.52 | |||||
Return on Total Capital | 27.9 | 26.64 | 18.52 | 14.66 | 14.53 | |||||
Return On Equity % | 231.06 | 162.32 | 77.62 | 42.82 | 29.28 | |||||
Return on Common Equity | 231.06 | 162.32 | 77.62 | 42.82 | 29.28 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 58.49 | 58 | 59.57 | 59.43 | 59.28 | |||||
SG&A Margin | 22.51 | 22.13 | 23.59 | 23.34 | 23.54 | |||||
EBITDA Margin % | 34.4 | 34.12 | 34.58 | 34.79 | 34.56 | |||||
EBITA Margin % | 31.83 | 31.7 | 31.71 | 31.85 | 31.78 | |||||
EBIT Margin % | 29.68 | 29.73 | 28.97 | 28.31 | 28.05 | |||||
Income From Continuing Operations Margin % | 24.87 | 23.81 | 21.72 | 21.56 | 20.3 | |||||
Net Income Margin % | 24.87 | 23.81 | 21.72 | 21.56 | 20.3 | |||||
Net Avail. For Common Margin % | 24.87 | 23.81 | 21.72 | 21.56 | 20.3 | |||||
Normalized Net Income Margin | 17.75 | 17.8 | 16.39 | 16.19 | 16.58 | |||||
Levered Free Cash Flow Margin | 14.56 | 11.61 | 15.01 | 21.2 | 13.5 | |||||
Unlevered Free Cash Flow Margin | 15.57 | 12.64 | 17.1 | 23.09 | 14.87 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.94 | 0.93 | 0.75 | 0.64 | 0.66 | |||||
Fixed Assets Turnover | 4.57 | 4.57 | 4.25 | 4.08 | 4.37 | |||||
Receivables Turnover (Average Receivables) | 4.7 | 4.45 | 4.15 | 4.12 | 4.05 | |||||
Inventory Turnover (Average Inventory) | 3.5 | 3.08 | 2.46 | 2.42 | 2.46 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.39 | 2.24 | 2.22 | 2.11 | 1.73 | |||||
Quick Ratio | 1.74 | 1.53 | 1.39 | 1.34 | 1.14 | |||||
Operating Cash Flow to Current Liabilities | 1.1 | 0.78 | 0.76 | 0.97 | 0.53 | |||||
Days Sales Outstanding (Average Receivables) | 77.69 | 82.01 | 87.97 | 88.8 | 90.07 | |||||
Days Outstanding Inventory (Average Inventory) | 104.21 | 118.7 | 148.41 | 151.48 | 148.63 | |||||
Average Days Payable Outstanding | 25.53 | 25.74 | 25.87 | 29.1 | 26.86 | |||||
Cash Conversion Cycle (Average Days) | 156.37 | 174.97 | 210.51 | 211.18 | 211.84 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 437.15 | 330.67 | 213.47 | 93.14 | 60.28 | |||||
Total Debt / Total Capital | 81.38 | 76.78 | 68.1 | 48.22 | 37.61 | |||||
LT Debt/Equity | 429.56 | 315.52 | 206.71 | 91.74 | 41.11 | |||||
Long-Term Debt / Total Capital | 79.97 | 73.26 | 65.94 | 47.5 | 25.65 | |||||
Total Liabilities / Total Assets | 88.12 | 84.63 | 75.14 | 59.85 | 49.55 | |||||
EBIT / Interest Expense | 18.4 | 18.11 | 8.66 | 9.34 | 12.77 | |||||
EBITDA / Interest Expense | 22.08 | 21.52 | 10.72 | 11.91 | 16.32 | |||||
(EBITDA - Capex) / Interest Expense | 18.5 | 17.91 | 9.1 | 10.32 | 14.7 | |||||
Total Debt / EBITDA | 1.62 | 1.59 | 2.32 | 1.59 | 1.36 | |||||
Net Debt / EBITDA | 1.05 | 1.13 | 1.94 | 1.29 | 0.84 | |||||
Total Debt / (EBITDA - Capex) | 1.93 | 1.91 | 2.73 | 1.84 | 1.51 | |||||
Net Debt / (EBITDA - Capex) | 1.25 | 1.36 | 2.29 | 1.49 | 0.94 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 17.78 | 6.68 | -0.52 | 0.07 | 6.99 | |||||
Gross Profit, 1 Yr. Growth % | 19.92 | 5.8 | 2.17 | -0.17 | 6.73 | |||||
EBITDA, 1 Yr. Growth % | 19.06 | 5.81 | 0.81 | -1.14 | 4.46 | |||||
EBITA, 1 Yr. Growth % | 20.45 | 6.23 | -0.47 | -1.49 | 4.75 | |||||
EBIT, 1 Yr. Growth % | 21.65 | 6.88 | -3.09 | -4.32 | 3.77 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 32.84 | 2.15 | -9.26 | -0.69 | 0.75 | |||||
Net Income, 1 Yr. Growth % | 32.84 | 2.15 | -9.26 | -0.69 | 0.75 | |||||
Normalized Net Income, 1 Yr. Growth % | 22.49 | 6.99 | -8.43 | -3.5 | 7.07 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 33.61 | 5.01 | -7.59 | -1.2 | 0.47 | |||||
Accounts Receivable, 1 Yr. Growth % | 6.86 | 17.99 | -2.87 | 4.44 | 13.02 | |||||
Inventory, 1 Yr. Growth % | 17.03 | 27.97 | 13.28 | -7.55 | 19.93 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 7.73 | 5.7 | 8.22 | 0.24 | -0.36 | |||||
Total Assets, 1 Yr. Growth % | 8.98 | 6.03 | 41 | -1.58 | 11.48 | |||||
Tangible Book Value, 1 Yr. Growth % | -33.59 | -51 | 411.81 | -95.52 | -1.99T | |||||
Common Equity, 1 Yr. Growth % | 58.33 | 37.26 | 128.02 | 58.95 | 40.07 | |||||
Cash From Operations, 1 Yr. Growth % | -5.47 | -18.15 | -1.45 | 26.43 | -14.38 | |||||
Capital Expenditures, 1 Yr. Growth % | -6.45 | 9.09 | -8.69 | -11.3 | -20.87 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -28.19 | -14.89 | 28.53 | 37.66 | -33.08 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -27.17 | -13.37 | 34.54 | 32.05 | -32.22 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.59 | 12.09 | 3.02 | -0.23 | 3.47 | |||||
Gross Profit, 2 Yr. CAGR % | 8.04 | 12.64 | 3.97 | 0.99 | 3.22 | |||||
EBITDA, 2 Yr. CAGR % | 7.97 | 14.17 | 3.28 | 0.75 | 3.15 | |||||
EBITA, 2 Yr. CAGR % | 7.44 | 15.25 | 2.82 | 0.01 | 3.25 | |||||
EBIT, 2 Yr. CAGR % | 7.4 | 16.36 | 1.77 | -2.65 | 1.47 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 8.16 | 16.49 | -3.72 | -5.07 | 0.03 | |||||
Net Income, 2 Yr. CAGR % | 8.16 | 16.49 | -3.72 | -5.07 | 0.03 | |||||
Normalized Net Income, 2 Yr. CAGR % | 7.23 | 16.95 | -1.02 | -4.85 | 3.68 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 13.37 | 18.45 | -1.49 | -4.45 | -0.37 | |||||
Accounts Receivable, 2 Yr. CAGR % | 2.1 | 12.29 | 7.06 | 0.72 | 8.65 | |||||
Inventory, 2 Yr. CAGR % | 5.4 | 22.38 | 20.4 | 2.34 | 5.3 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 11.3 | 6.71 | 6.95 | 4.15 | -0.06 | |||||
Total Assets, 2 Yr. CAGR % | 10.02 | 7.49 | 22.27 | 17.8 | 4.75 | |||||
Tangible Book Value, 2 Yr. CAGR % | -37.97 | -42.95 | 58.37 | -52.13 | -8.06 | |||||
Common Equity, 2 Yr. CAGR % | 30.36 | 47.42 | 76.91 | 90.38 | 49.21 | |||||
Cash From Operations, 2 Yr. CAGR % | 7.8 | -12.04 | -10.18 | 11.62 | 4.04 | |||||
Capital Expenditures, 2 Yr. CAGR % | -0.78 | 1.02 | -0.2 | -10 | -16.22 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 5.37 | -20.63 | 4.59 | 34.78 | -2.29 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 4.68 | -19.42 | 7.96 | 34.85 | -3.86 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 4.81 | 7.29 | 7.72 | 2.02 | 2.12 | |||||
Gross Profit, 3 Yr. CAGR % | 4.51 | 7.29 | 9.03 | 2.57 | 2.87 | |||||
EBITDA, 3 Yr. CAGR % | 6.22 | 7.25 | 9.53 | 2.41 | 2.56 | |||||
EBITA, 3 Yr. CAGR % | 6.14 | 7.04 | 9.75 | 2.04 | 2.21 | |||||
EBIT, 3 Yr. CAGR % | 6.15 | 7.23 | 9.48 | 0.43 | 0.16 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 5.28 | 6.12 | 7.18 | -2.72 | -3.17 | |||||
Net Income, 3 Yr. CAGR % | 5.28 | 6.12 | 7.18 | -2.72 | -3.17 | |||||
Normalized Net Income, 3 Yr. CAGR % | 5.1 | 7.15 | 7.79 | -1.06 | -0.27 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 13.45 | 10.52 | 9.05 | -1.39 | -2.84 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.54 | 7.14 | 6.99 | 6.18 | 4.66 | |||||
Inventory, 3 Yr. CAGR % | 6.89 | 12.44 | 19.27 | 10.25 | 7.89 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 22.63 | 9.4 | 7.21 | 4.67 | 2.63 | |||||
Total Assets, 3 Yr. CAGR % | -6.01 | 8.67 | 17.67 | 13.74 | 15.66 | |||||
Tangible Book Value, 3 Yr. CAGR % | -31.31 | -42.66 | 18.54 | -51.75 | 62.95 | |||||
Common Equity, 3 Yr. CAGR % | -38.33 | 32.62 | 70.49 | 70.71 | 71.87 | |||||
Cash From Operations, 3 Yr. CAGR % | 7.33 | -1.66 | -8.64 | 0.66 | 2.18 | |||||
Capital Expenditures, 3 Yr. CAGR % | 18.84 | 2.4 | -2.33 | -4.04 | -13.78 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 5.76 | -1.87 | -6.79 | 15.63 | 7.36 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 5.13 | -1.72 | -4.4 | 16.35 | 7.8 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 5.15 | 5.18 | 4.09 | 4.22 | 6 | |||||
Gross Profit, 5 Yr. CAGR % | 5.01 | 4.82 | 4.29 | 4.72 | 6.67 | |||||
EBITDA, 5 Yr. CAGR % | 5.74 | 5.28 | 5.03 | 4.6 | 7.06 | |||||
EBITA, 5 Yr. CAGR % | 5.66 | 5.45 | 4.8 | 4.17 | 7.24 | |||||
EBIT, 5 Yr. CAGR % | 5.63 | 5.44 | 4.38 | 3.16 | 6.35 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 5.85 | 103.44 | 1.58 | 1.5 | 4.26 | |||||
Net Income, 5 Yr. CAGR % | 5.85 | 103.44 | 1.58 | 1.5 | 4.26 | |||||
Normalized Net Income, 5 Yr. CAGR % | 5.56 | 5.2 | 2.6 | 2.18 | 6.29 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 11.75 | 115.91 | 7.22 | 4.27 | 5.18 | |||||
Accounts Receivable, 5 Yr. CAGR % | 4.6 | 6.25 | 4.32 | 4.53 | 7.65 | |||||
Inventory, 5 Yr. CAGR % | 6.27 | 11.01 | 12.1 | 8.29 | 13.47 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 13.42 | 13.87 | 16.1 | 7.27 | 4.24 | |||||
Total Assets, 5 Yr. CAGR % | -7.87 | -9.23 | 4.42 | 12.23 | 12.32 | |||||
Tangible Book Value, 5 Yr. CAGR % | -29.08 | -37.8 | -4.06 | -46.65 | 7.08 | |||||
Common Equity, 5 Yr. CAGR % | -30.71 | -25.74 | -6 | 53.26 | 61.64 | |||||
Cash From Operations, 5 Yr. CAGR % | 3.05 | -2.6 | -0.05 | 3.45 | -3.76 | |||||
Capital Expenditures, 5 Yr. CAGR % | 11.17 | 15.53 | 10.83 | -2.75 | -8.14 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 0.01 | -7.14 | 5.29 | 11.41 | -4.86 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 0.01 | -6.85 | 6.25 | 11.54 | -4.05 |
- Stock Market
- Stocks
- WAT Stock
- Financials Waters Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















